Trishula Therapeutics is a clinical-stage cancer immunotherapy company developing TTX-030, a first-in-class anti-CD39 antibody.

Biotechnology

Trishula Therapeutics

Trishula Therapeutics' headquarters in South San Francisco, CA, United States

Anil Singhal

Siddhartha Mitra

Alan Luk

Luke Evnin

Nina Kjellson

John A. Hohneker

Scott Clarke

Scott Brun

The Leadership Team at Trishula Therapeutics is responsible for driving the strategic vision and operational execution of the company’s clinical programs, particularly the development of TTX-030. This team, comprising experts in immunology, translational sciences, and manufacturing chemistry, leads key decision-making processes, fostering collaboration across departments to advance innovative cancer immunotherapy solutions. Their collective expertise ensures alignment on research and development goals while navigating the complexities of clinical trials and regulatory compliance.

Leadership Team

The Clinical Operations and Data Management team at Trishula Therapeutics is responsible for the planning, execution, and management of clinical trials for their flagship anti-CD39 antibody, TTX-030. This team ensures the efficient operation of clinical studies, oversees patient data integrity, compliance with regulatory standards, and facilitates data analysis to advance the development of cancer immunotherapy solutions.

Trishula Therapeutics

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations and Data Management

Offices

Trishula Therapeutics

Org chart

Board & advisors

Teams

Leadership Team

Clinical Operations and Data Management

Offices

Related companies